aducanumab
FDA staffers defend Aduhelm approval in JAMA editorial
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, Eisai, fda, neurology, regulatory
0 Comment
News/ News/ Sales and Marketing
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, Biogen, Drug pricing, Eisai, neurology
0 Comment
Consumer group seeks resignation of top FDA staffers over Aduhelm okay
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, fda, Janet Woodcock, neurology, senior management
0 Comment
And then there were three: another FDA adcomm member quits over Aduhelm
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, fda, neurology
0 Comment
Double resignation over Aduhelm approval depletes FDA’s CNS adcomm
Phil Taylor
aducanumab, Aduhelm, Alzheimer's, amyloid, Biogen, central nervous system, fda, neurology, regulatory
0 Comment
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, Biogen, Drug pricing, fda, ICER, neurology
0 Comment
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab
Phil Taylor
aducanumab, Aduhelm, Alzheimer's disease, amyloid, Biogen, fda, neurology
0 Comment
FDA grew too close to Biogen during Alzheimer’s drug development, doctors say
Richard Staines
aducanumab, Alzheimer's, Biogen, Eisia, neurology, R&D
0 Comment